InvestorWire NewsRoom


Can-Fite BioPharma Ltd. (NYSE American: CANF) Featured in Virtual Coverage of Benzinga’s Global Small Cap Conference
December 8, 2020

Can-Fite BioPharma Ltd. (NYSE American: CANF) Featured in Virtual Coverage of Benzinga’s Global Small Cap Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) isanadvanced clinical stage drug development company with a novel therapeutic approach for the treatment of liver and inflammatory diseases, addressing multi-billion dollar markets.

Oral drugs with proven safety and efficacy – Piclidenoson and Namodenoson are Phase III assets in psoriasis and liver cancer and Namodenoson showed strong efficacy in a Phase II NASH study. Piclidenoson has recently been approved by FDA and IRBs to commence enrollment of patients with moderate COVID-19 in a Phase II study.

Intellectual property portfolio – consists of 15 patent families issued and pending.

Corporate partnerships – Piclidenoson and Namodenoson have been out-licensed in select territories with ~$18 million received to date.

Financially well positioned – the company is well positioned to conduct all its clinical development programs and G&A for > 1 year

For further details on Benzinga’s Global Small Cap Conference and other events, visit

About InvestorBrandNetwork’s Virtual Coverage

The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, covers dozens of investor conferences and online events as part of its ongoing service to the investment community. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN utilizes social media and syndicated articles to maximize the visibility of each featured session.

For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its many event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorBrandNetwork (IBN)
Los Angeles, California
310.299.1717 Office
[email protected]

Recent Articles

Release Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).